Marinus Pharmaceuticals, Radnor, PA

Marinus Pharmaceuticals

www.marinuspharma.com

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and ...

More>>

Number of Employees: 100-250
Annual Revenue: $10-50 Million

www.marinuspharma.com
5 Radnor Corporate Center 100 Matsonford Road Suite 500
Radnor, PA USA 19087
Phone: 484.801.4670

Executives

Name	Title	Contact Details
Marc Bellisario	Sr. Director, R&D Program Management	Profile
Michael Saporito	Vice President of Research and Preclinical Development	Profile
Michael Barr	Sr Director Human Resources - Marinus Pharmaceutical	Profile
Steven Pfanstiel	Chief Financial Officer	Profile
Scott Braunstein	Chief Executive Officer	Profile

Similar Companies

DocShop Pro

DocShop Pro provides the best prices for supplies for doctors, as well as an inventory management system for practice managers. Join DocShop Pro today!

BioBlast Pharma

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.

HR Execs on the Move